ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario

BACKGROUND: Anaplastic lymphoma kinase (ALK) inhibitors have shown significant efficacy in ALK -rearranged non-small cell lung cancer (NSCLC) patients with good performance status (PS) in multiple randomised studies. However, there is limited data on patients with poor performance status. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ajaykumar, Kapoor, Akhil, Noronha, Vanita, Patil, Vijay, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendru, Kaushal, Rajiv, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377804/
https://www.ncbi.nlm.nih.gov/pubmed/36072236
http://dx.doi.org/10.3332/ecancer.2022.1407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377804/
https://www.ncbi.nlm.nih.gov/pubmed/36072236
http://dx.doi.org/10.3332/ecancer.2022.1407

Ejemplares similares